What Ziccum does

Ziccum is a Sweden-based, early-stage biotechnology company founded in 2017 in Lund with a stated focus on developing new dry-powder versions of vaccines and biologic pharmaceuticals. Per the provided firmographics, the company's functional purpose is to reformulate temperature-sensitive biologics into dry-powder formats, an approach that, if successful, would enable room-temperature-stable storage and transport and reduce dependence on the cold chain. The firmographic core-technology field is blank in the input, and no patents, proprietary platform name, or specific mechanism of action are documented in the available data, so the precise formulation/drying method cannot be confirmed from this source alone.

The company's operating posture as evidenced by the input is pre-commercial: a 1-10 employee headcount, a two-person named leadership team (Founder & CEO Goran Conradsson and CFO Michael Owens), and only one disclosed financing event — an August 2018 EISMEA (EU SME instrument) grant of $83,304 — with no subsequent funding rounds, product launches, partnerships, named customers, pricing, or revenue streams listed. The corporate website (ziccum.com) was observed to have lapsed into an Expired Registration Recovery Policy page hosted by Key-Systems GmbH (the domain registrar in St. Ingbert, Germany), and no active operating geography, distribution channel, or regulatory milestone is documented in the source.

On data quality: a 'financials' block attached to this record contains revenue, EBITDA, operating income, and net income figures (e.g., $626.5 billion revenue in 2023 with EBITDA of approximately -$2 quadrillion) that are multiple orders of magnitude inconsistent with the rest of the profile (1-10 employees, a sub-$100K early grant, 2017 founding). These figures appear to be data contamination from an unrelated large-cap entity and have not been used as evidence in this assessment.

Name

Ziccum

Legal name

Key-Systems GmbH

Website

https://ziccum.com

Company type

Private

Founded year

2017

Operating status

Closed

Headcount range

1–10 employees

Short description

Ziccum is a Swedish biotech (founded 2017, Lund, 1-10 employees) developing dry-powder formulations of vaccines and biologic pharmaceuticals, with pre-commercial operations and no disclosed revenue, customers, or productized assets in the input.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Formulation Development

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Manufacturing & Fill-Finish (HLAIAEAJ)

akta.pro secondary industries

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Lyophilization (Freeze-Drying) CDMO (HLAGABAI)

Keywords

• Dry powder vaccines
• Biologic pharmaceuticals
• Vaccine formulations
• Biopharmaceutical development
• Therapeutic stabilization

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Core offering

Ziccum develops new dry-powder formulations of vaccines and biologic pharmaceuticals, aiming to create thermostable versions of temperature-sensitive biological drugs. The company focuses on pharmaceutical formulation research and development, producing alternative dosage formats that reduce dependence on cold-chain logistics. Operations are early-stage, with a small team based in Lund, Sweden.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Vaxxas: Australian biotech developing a needle-free, thermostable vaccine delivery patch (HD-MAP). Closely comparable to Ziccum because both pursue alternative, cold-chain-light vaccine administration/formulation routes aimed at improving vaccine stability and global access.
• Vaxart: U.S. clinical-stage biotech developing oral pill vaccines that eliminate the need for needles and cold-chain distribution. Directly comparable to Ziccum's mission of producing thermostable, easy-to-administer vaccine dosage forms.

Broad incumbents

• Emergent BioSolutions: Large biopharmaceutical company specializing in vaccines and antibody therapeutics for public health threats, with established fill-finish and lyophilization capabilities. Comparable as a large incumbent operating in vaccine formulation and manufacturing adjacent to Ziccum's dry-powder work.
• Hovione: Global CDMO with strong spray-drying and particle-engineering capabilities for inhalable and dry-powder drug formulations. Comparable to Ziccum because it has deep expertise in turning biologics into dry-powder forms — a capability Ziccum is also building.
• Catalent (now part of Novo Holdings): Major global CDMO with extensive biologics fill-finish, lyophilization, and formulation capabilities, including dry-powder and inhaled formats. Relevant as a much larger peer that could either partner with or outcompete a small dry-powder vaccine platform.
• Novavax: Vaccine developer using recombinant protein nanoparticle technology with thermostable formulations. Adjacent peer because of its work on stable, cold-chain-light vaccine products targeted at global health markets.

Emerging players

• Stablepharma: UK-based biotech developing fully stable, fridge-free vaccine and biologic formulations using novel stabilization technology. Direct emerging peer addressing the same thermostable vaccine/biologic problem that Ziccum targets.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company developing self-amplifying and conventional mRNA vaccines with formulation work aimed at reducing cold-chain requirements. Comparable emerging player targeting thermostable vaccine/biologic delivery.
• Arecor: UK-based formulation company using its Arestat platform to create stable, liquid and dry formulations of biologics, including vaccines and therapeutics. Comparable emerging peer working on biologic stability — a core problem space for Ziccum.

Regional players

• Vakzine Projekt Management: German vaccine development consultancy and project management firm with expertise in vaccine R&D and translational programs. Comparable as a regional (DACH) player operating in the same vaccine development ecosystem where Ziccum's German entity is registered.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights4 records

Customer concentration

• Xx.com/ziccum

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ziccum